IXICO today announces its final results for the sixteen month period ended 30 September 2014.
- During the period IXICO became a public company and continued its evolution in the emerging and fast moving digital healthcare market with a focus on brain health
- Contracts signed with four significant new customers in a range of disease indications
- New opportunities in Huntington’s disease specialisation
- International commercial alliance with VirtualScopics Inc. signed in July enhances IXICO’s ability to provide clinical trial industry with global operational capabilities
- IXICO selected as industry partner in Dementias Platform UK
- Significant investment in digital health
- Financial performance in line with market and board expectations